Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma.

Trial Profile

Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Melphalan (Primary) ; Prednisone (Primary) ; Thalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RMPT
  • Most Recent Events

    • 09 May 2016 Status changed from active, no longer recruiting to completed.
    • 18 Mar 2010 Planned end date (Feb 2011) added as reported by ClinicalTrials.gov.
    • 05 Dec 2009 Results presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH 2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top